Caroline Robert, Gustave Roussy, France:

LBA4
COMBI-v: A randomised, open-label, Phase III study comparing the combination of dabrafenib and trametinib to vemurafenib as first- line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma: